Validated risk models for stratification of SMM patients
| Risk model . | Groups . | Number of patients (%) . | TTP, y . | Progression at 5 y . |
|---|---|---|---|---|
| Mayo Clinic model | ||||
| ≥3 g/dL serum M-protein plus ≥10% BMPCs | High risk | 76 (25) | 2 | 25 |
| <3 g/dL serum M-protein plus ≥10% BMPCs | Intermediate risk | 115 (42) | 8 | 51 |
| ≥3 g/dL serum M-protein plus <10% BMPCs | Low risk | 82 (30) | 19 | 76 |
| Spanish Myeloma Group model | ||||
| ≥95% of aberrant PCs by MFC plus immunoparesis | High risk | 28 (31) | 1.9 | 4 |
| ≥95% of aberrant PCs by MFC or immunoparesis | Intermediate risk | 22 (25) | 6 | 46 |
| None of the above | Low risk | 39 (44) | NR | 72 |
| Risk model . | Groups . | Number of patients (%) . | TTP, y . | Progression at 5 y . |
|---|---|---|---|---|
| Mayo Clinic model | ||||
| ≥3 g/dL serum M-protein plus ≥10% BMPCs | High risk | 76 (25) | 2 | 25 |
| <3 g/dL serum M-protein plus ≥10% BMPCs | Intermediate risk | 115 (42) | 8 | 51 |
| ≥3 g/dL serum M-protein plus <10% BMPCs | Low risk | 82 (30) | 19 | 76 |
| Spanish Myeloma Group model | ||||
| ≥95% of aberrant PCs by MFC plus immunoparesis | High risk | 28 (31) | 1.9 | 4 |
| ≥95% of aberrant PCs by MFC or immunoparesis | Intermediate risk | 22 (25) | 6 | 46 |
| None of the above | Low risk | 39 (44) | NR | 72 |
MFC, multiparametric flow cytometry; NR, not reached; PCs, plasma cells; TTP, time to progression.